BackgroundLong acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11–12 days in human.MethodsABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving ABT (160 or 320 mg) given weekly and LPV/r given twice daily.ResultsAt week 7, the decline of HIV-1 RNA from baseline was 1.9 (1.3–2.3) log10 and 2.2 (1.6–2.7) log10 copies/ml, and suppression of HIV-1 RNA to below 50 copies/ml was achieved in 11.1 % (1/9) and 55.6 % (5/9) patients, for the 160 and 320 mg dose group respectively.ConclusionA clear dose-efficacy correlation of ABT was demonstrated. ABT combining with LPV/r is a promising two-drug regimen to be tested in larger patient population.

No abstract

Theoretical derivation of local resistance coefficient of sudden expansion tube is presented. Several assumptions are analyzed in the theoretical derivation. That the head loss shall be neglected is affirmed. Experimental data proves that the pressure before and after sudden expansion section is basically the same. That the friction force on the side face of control body is neglected is denied and it is pointed out that such neglect is the main cause for error between theoretical calculation and actual measurement. Experimental device for measuring local resistance coefficient is designed in combination with theoretical derivation process. Optimal gradually varied flow section is selected after sudden expansion pipe in Bernoulli equation based on variation of piezometer tube head. It is pointed out in accordance with experimental data analysis that the value of local resistance coefficient of sudden expansion tube determined through experimental data is closer to the actual situation during pipeline design.

No abstract

No abstract